2023
Challenges to Achieving HCV Micro-Elimination in People With HIV in the United States: Provider Perspectives and the Role of Implicit Bias
DiDomizio E, Chandra D, Nichols L, Villanueva M, Altice F. Challenges to Achieving HCV Micro-Elimination in People With HIV in the United States: Provider Perspectives and the Role of Implicit Bias. Health Promotion Practice 2023, 24: 998-1008. PMID: 37440258, DOI: 10.1177/15248399231169928.Peer-Reviewed Original ResearchMeSH KeywordsBias, ImplicitDrug UsersHepacivirusHepatitis CHIV InfectionsHumansSubstance Abuse, IntravenousUnited StatesConceptsNominal group techniqueHealth care decisionsProvider perspectivesEligibility criteriaHIV/HCVEffective antiviral medicationsPatient eligibility criteriaFacilitators of treatmentMicro-EliminationHCV treatmentAntiviral medicationsOpioid epidemicProvider knowledgePatient involvementPatient engagementDifferent clinicsRelated stigmaHCVCare decisionsHIVPatientsTreatmentGroup sessionsMost barriersFocus group sessionsCosts and cost‐effectiveness of a collaborative data‐to‐care intervention for HIV treatment and care in the United States
Shrestha R, Fanfair R, Randall L, Lucas C, Nichols L, Camp N, Brady K, Jenkins H, Altice F, DeMaria A, Villanueva M, Weidle P. Costs and cost‐effectiveness of a collaborative data‐to‐care intervention for HIV treatment and care in the United States. Journal Of The International AIDS Society 2023, 26: e26040. PMID: 36682053, PMCID: PMC9867888, DOI: 10.1002/jia2.26040.Peer-Reviewed Original ResearchConceptsCare armHIV careCare patientsIntervention armCare interventionsHealth departmentsHIV care interventionsHIV care outcomesHIV care providersHealthcare provider perspectiveHIV clinicHIV treatmentCare providersControl trialCare outcomesMicrocosting approachCare programCare servicesSurveillance dataSimilar interventionsIncremental costIntervention costsProvider perspectivesCareAverage cost
2022
Strengthening systems of care for people with or at risk for HIV, HCV and opioid use disorder: a call for enhanced data collection
Eller AJ, DiDomizio EE, Madden LM, Oliva JD, Altice FL, Johnson KA. Strengthening systems of care for people with or at risk for HIV, HCV and opioid use disorder: a call for enhanced data collection. Annals Of Medicine 2022, 54: 1714-1724. PMID: 35775786, PMCID: PMC9377256, DOI: 10.1080/07853890.2022.2084154.Peer-Reviewed Original ResearchMeSH KeywordsData CollectionHepacivirusHepatitis CHIV InfectionsHumansOpioid-Related DisordersUnited StatesConceptsCascade of careHuman immunodeficiency virusOpioid use disorderHepatitis C virusPublic health planningUse disordersCo-occurring opioid use disorderHealth planningBurden of diseaseSystems of careQuality improvement activitiesOUD cascadeTreatment initiationImmunodeficiency virusC virusPatient outcomesTreatment accessPayer sourceTreatment retentionHealth systemHealthcare systemCareSyndemicDisordersVirusNews events and their relationship with US vape sales: an interrupted time series analysis
Janmohamed K, Nakamura-Sakai S, Soale AN, Forastiere L, Altice FL, Kumar N. News events and their relationship with US vape sales: an interrupted time series analysis. BMC Public Health 2022, 22: 479. PMID: 35272644, PMCID: PMC8915465, DOI: 10.1186/s12889-022-12858-x.Peer-Reviewed Original Research
2021
Preferences for pre-exposure prophylaxis among U.S. military men who have sex with men: results of an adaptive choice based conjoint analysis study
Gutierrez JI, Dubov A, Altice FL, Vlahov D. Preferences for pre-exposure prophylaxis among U.S. military men who have sex with men: results of an adaptive choice based conjoint analysis study. Military Medical Research 2021, 8: 32. PMID: 34006328, PMCID: PMC8132436, DOI: 10.1186/s40779-021-00323-6.Peer-Reviewed Original ResearchConceptsDaily tabletHuman immunodeficiency virus (HIV) infectionMilitary healthcare settingsImmunodeficiency virus infectionPre-exposure prophylaxisU.S. military menTelehealth visitsResultsA totalVirus infectionProvider typeUtility scoresPrEP programHealthcare settingsMental healthMilitary providersProphylaxisMenSexInjectionConjoint analysis studyMilitary menService deliverySocial media groupsMedia groupsMedicationsModelling the intervention effect of opioid agonist treatment on multiple mortality outcomes in people who inject drugs: a three-setting analysis
Stone J, Degenhardt L, Grebely J, Larney S, Altice FL, Smyrnov P, Rahimi-Movaghar A, Alavi M, Young AM, Havens JR, Miller WC, Hickman M, Vickerman P. Modelling the intervention effect of opioid agonist treatment on multiple mortality outcomes in people who inject drugs: a three-setting analysis. The Lancet Psychiatry 2021, 8: 301-309. PMID: 33640039, PMCID: PMC8255389, DOI: 10.1016/s2215-0366(20)30538-1.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentDrug-related deathsOAT coverageDrug-related harmAgonist treatmentHepatitis C virus transmissionC virus transmissionOverall health benefitsUK National InstituteNational InstituteHIV 0OAT retentionHIV mortalityInjury 3Opioid dependenceMortality outcomesUS National InstitutesHCV-2Overdose deathsSignificant additional effectIntervention effectsDrug abuseHealth benefitsMortalityDeathThe opioid crisis and HIV in the USA: deadly synergies
Hodder SL, Feinberg J, Strathdee SA, Shoptaw S, Altice FL, Ortenzio L, Beyrer C. The opioid crisis and HIV in the USA: deadly synergies. The Lancet 2021, 397: 1139-1150. PMID: 33617769, DOI: 10.1016/s0140-6736(21)00391-3.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAnalgesics, OpioidBlack or African AmericanCase-Control StudiesDisease OutbreaksEvidence-Based MedicineFemaleFentanylHealth Services AccessibilityHispanic or LatinoHIV InfectionsHumansMaleNeedle SharingOpiate OverdoseOpioid EpidemicOpioid-Related DisordersSocial StigmaUnited StatesWhite PeopleYoung AdultConceptsNew HIV diagnosesHIV diagnosisOpioid epidemicHIV preventionMultiple evidence-based interventionsGreat public health problemRecent HIV outbreaksOpioid overdose death ratesOpioid use disorderLarge central metropolitan areasPublic health problemOverdose death ratesComprehensive health careEvidence-based interventionsDeadly synergyHIV acquisitionSynthetic opioid fentanylSyringe sharingHIV outbreakUse disordersOpioid fentanylTreatment servicesHealth problemsOpioid crisisDeath rate
2020
Hazardous alcohol use, antiretroviral therapy receipt, and viral suppression in people living with HIV who inject drugs in the United States, India, Russia, and Vietnam.
Wagman JA, Wynn A, Matsuzaki M, Gnatienko N, Metsch LR, Del Rio C, Feaster DJ, Nance RM, Whitney BM, Delaney JAC, Kahana SY, Crane HM, Chandler RK, Elliott JC, Altice F, Lucas GM, Mehta SH, Hirsch-Moverman Y, El-Sadr WM, Vu Q, Nguyen Thanh B, Springer SA, Tsui JI, Samet JH. Hazardous alcohol use, antiretroviral therapy receipt, and viral suppression in people living with HIV who inject drugs in the United States, India, Russia, and Vietnam. AIDS 2020, 34: 2285-2294. PMID: 33048870, PMCID: PMC7951611, DOI: 10.1097/qad.0000000000002716.Peer-Reviewed Original ResearchConceptsHazardous alcohol useFormer injection drug useART receiptViral suppressionInjection drug useLow-middle income countriesAlcohol useAntiretroviral therapyMiddle-income countriesDrug useAlcohol Use Disorders Identification Test (AUDIT) scoresHIV viral suppressionAlcohol Use Disorders Identification TestDisorders Identification TestTherapy receiptHIV continuumMean ageHigh-income countriesCare outcomesLogistic regressionUpper middle-income countriesPLHIVDrugsIdentification TestHIVModeling Combination Hepatitis C Virus Treatment and Prevention Strategies in a Network of People Who Inject Drugs in the United States
Zelenev A, Li J, Shea P, Hecht R, Altice FL. Modeling Combination Hepatitis C Virus Treatment and Prevention Strategies in a Network of People Who Inject Drugs in the United States. Clinical Infectious Diseases 2020, 72: 755-763. PMID: 32060534, PMCID: PMC7935393, DOI: 10.1093/cid/ciaa142.Peer-Reviewed Original ResearchConceptsOpioid agonist therapySyringe services programHepatitis C virus (HCV) treatmentC virus treatmentHCV prevalenceHCV microeliminationHCV TasPHCV treatmentPrevention strategiesVirus treatmentTasP strategyHigh HCV prevalenceMicroelimination of HCVHuman immunodeficiency virusHCV treatment coverageOAT coverageAgonist therapyImmunodeficiency virusTreatment coverageMicroeliminationPrevention impactPrevalenceComplimentary interventionsHCVPWID
2019
Implementing Data to Care-What Are the Costs for the Health Department?
Neblett Fanfair R, Shrestha RK, Randall L, Lucas C, Nichols L, Camp NM, Brady K, Jenkins H, Altice F, Villanueva M, DeMaria A. Implementing Data to Care-What Are the Costs for the Health Department? JAIDS Journal Of Acquired Immune Deficiency Syndromes 2019, 82 Suppl 1: s57-s61. PMID: 31425397, DOI: 10.1097/qai.0000000000001968.Peer-Reviewed Original ResearchEstimated Impact of Targeted Pre-Exposure Prophylaxis: Strategies for Men Who Have Sex with Men in the United States
Elion RA, Kabiri M, Mayer KH, Wohl DA, Cohen J, Beaubrun AC, Altice FL. Estimated Impact of Targeted Pre-Exposure Prophylaxis: Strategies for Men Who Have Sex with Men in the United States. International Journal Of Environmental Research And Public Health 2019, 16: 1592. PMID: 31067679, PMCID: PMC6539923, DOI: 10.3390/ijerph16091592.Peer-Reviewed Original ResearchConceptsYoung Latino MSMYoung Black MSMPre-exposure prophylaxisBlack MSMLatino MSMPrEP useHIV Incidence Risk IndexHuman immunodeficiency virus (HIV) transmissionUse of PrEPNon-PrEP usersLowest NNTHIV infectionNNT valuesHIV prevalenceHIV epidemicHIV preventionMSM populationSubsequent infectionInfection reductionMSMPrevalenceIncidenceVirus transmissionPrEPProphylaxis
2018
Stigma and Shame Experiences by MSM Who Take PrEP for HIV Prevention: A Qualitative Study
Dubov A, Galbo P, Altice FL, Fraenkel L. Stigma and Shame Experiences by MSM Who Take PrEP for HIV Prevention: A Qualitative Study. American Journal Of Men's Health 2018, 12: 1843-1854. PMID: 30160195, PMCID: PMC6199453, DOI: 10.1177/1557988318797437.Peer-Reviewed Original ResearchConceptsPrEP stigmaPre-exposure prophylaxis uptakeExperiences of MSMHIV-negative menPrEP-related stigmaHealth care professionalsPrEP useHIV preventionHIV stigmaMSM communityExperiences of stigmaCondom usePrEP programConstant comparison techniquesPrEPSemistructured interviewsMSMStigmaLack of literatureMenQualitative studyMedicationsChemsexA multisite, longitudinal study of risk factors for incarceration and impact on mental health and substance use among young transgender women in the USA
Hughto JMW, Reisner SL, Kershaw TS, Altice FL, Biello KB, Mimiaga MJ, Garofalo R, Kuhns LM, Pachankis JE. A multisite, longitudinal study of risk factors for incarceration and impact on mental health and substance use among young transgender women in the USA. Journal Of Public Health 2018, 41: 100-109. PMID: 29474682, PMCID: PMC6490767, DOI: 10.1093/pubmed/fdy031.Peer-Reviewed Original ResearchConceptsYoung transgender womenIllicit drug useRisk factorsTransgender womenRecent incarcerationDrug useSignificant independent predictorsIndividual risk factorsSubstance use disordersIndependent predictorsDepressive symptomsGeneral populationUse disordersMultilevel interventionsSomatic symptomsPoor healthRecent homelessnessMental healthStudy periodSubstance useWomenMixed effects modelsLongitudinal studySymptomsEffects model
2017
Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study
Zelenev A, Li J, Mazhnaya A, Basu S, Altice FL. Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study. The Lancet Infectious Diseases 2017, 18: 215-224. PMID: 29153265, PMCID: PMC5860640, DOI: 10.1016/s1473-3099(17)30676-x.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntiviral AgentsChemopreventionCitiesComputer SimulationDisease Transmission, InfectiousFemaleHepatitis CHumansMaleMiddle AgedModels, StatisticalPrevalenceSubstance Abuse, IntravenousSurveys and QuestionnairesTime FactorsTreatment OutcomeUnited StatesYoung AdultConceptsBaseline HCV prevalenceHepatitis C virusHCV prevalenceInjection partnersPrevention strategiesTreatment coverageTransmission of HCVHepatitis C virus (HCV) treatmentHCV elimination strategySuccessful HCV treatmentC virus treatmentInjection drug usersHCV treatment coverageAdditional network memberHCV treatmentActing antiviralsC virusChronic infectionVirus treatmentDrug usersPrevalenceDrug abuseDrugsNational InstitutePreventionLeveraging the U.S. Criminal Justice System to Access Women for HIV Interventions
Meyer JP, Muthulingam D, El-Bassel N, Altice FL. Leveraging the U.S. Criminal Justice System to Access Women for HIV Interventions. AIDS And Behavior 2017, 21: 3527-3548. PMID: 28534199, PMCID: PMC5699977, DOI: 10.1007/s10461-017-1778-6.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHIV interventionsCJ systemGender-stratified analysesEffective implementation strategiesHIV treatmentHIV preventionIntervention deliveryPrevention programsTreatment programUnique interventionsWomenInvolved womenFurther studiesInterventionProgram effectivenessImplementation strategiesPreventionCohort profile: seek, test, treat and retain United States criminal justice cohort
Chandler R, Gordon MS, Kruszka B, Strand LN, Altice FL, Beckwith CG, Biggs ML, Cunningham W, Chris Delaney JA, Flynn PM, Golin CE, Knight K, Kral AH, Kuo I, Lorvick J, Nance RM, Ouellet LJ, Rich JD, Sacks S, Seal D, Spaulding A, Springer SA, Taxman F, Wohl D, Young JD, Young R, Crane HM. Cohort profile: seek, test, treat and retain United States criminal justice cohort. Substance Abuse Treatment, Prevention, And Policy 2017, 12: 24. PMID: 28511680, PMCID: PMC5433052, DOI: 10.1186/s13011-017-0107-4.Peer-Reviewed Original ResearchConceptsHIV risk behaviorsTreatment cascadeViral loadHIV RNA viral loadCD4 T-cell countRisk behaviorsSubstance useT-cell countsHepatitis C infectionRNA viral loadInjection drug useHealth Related QualityHIV treatment cascadeUnprotected sexual intercourseHealth care accessRecent polysubstance useC infectionViral suppressionHIV diagnosisHIV infectionMedian ageRelated qualityCriminal justice involvementART treatmentCohort membersGender Differences in HIV Risk Behaviors Among Persons Involved in the U.S. Criminal Justice System and Living with HIV or at Risk for HIV: A “Seek, Test, Treat, and Retain” Harmonization Consortium
Loeliger KB, Biggs ML, Young R, Seal DW, Beckwith CG, Kuo I, Gordon MS, Altice FL, Ouellet LJ, Cunningham WE, Young JD, Springer SA. Gender Differences in HIV Risk Behaviors Among Persons Involved in the U.S. Criminal Justice System and Living with HIV or at Risk for HIV: A “Seek, Test, Treat, and Retain” Harmonization Consortium. AIDS And Behavior 2017, 21: 2945-2957. PMID: 28188460, PMCID: PMC5552433, DOI: 10.1007/s10461-017-1722-9.Peer-Reviewed Original ResearchConceptsHIV risk behaviorsRisk behaviorsHIV risk reduction interventionsHIV-negative participantsHIV-positive womenHIV-positive menMultilevel mixed-effects logistic regression modelSero-discordant partnersMixed effects logistic regression modelsCondomless sexual intercourseRisk reduction interventionsLogistic regression modelsCJ populationsBehavior Assessment ToolHIV transmissionCriminal justice populationsHigher oddsHIVReduction interventionsSexual intercourseLarge-scale studiesBaseline dataInjection equipmentJustice populationsAssessment toolInnovative Program Delivery and Determinants of Frequent Visitation to a Mobile Medical Clinic in an Urban Setting
Gibson BA, Morano JP, Walton MR, Marcus R, Zelenev A, Bruce RD, Altice FL. Innovative Program Delivery and Determinants of Frequent Visitation to a Mobile Medical Clinic in an Urban Setting. Journal Of Health Care For The Poor And Underserved 2017, 28: 643-662. PMID: 28529215, DOI: 10.1353/hpu.2017.0065.Peer-Reviewed Original ResearchConceptsMobile medical clinicMedical clinicsInjection drug useVulnerable populationsHealth careHealth insurance coveragePatient characteristicsContinuous health careAcute careAffordable Care ActDrug useNegative binomial regressionInsurance coverageCare ActCareCertain populationsUtilization patternsBinomial regressionClinicVisitsProgram deliveryUnique clientsNew HavenPopulationSpecific indicators
2016
Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees
Dolan K, Wirtz AL, Moazen B, Ndeffo-mbah M, Galvani A, Kinner SA, Courtney R, McKee M, Amon JJ, Maher L, Hellard M, Beyrer C, Altice FL. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. The Lancet 2016, 388: 1089-1102. PMID: 27427453, DOI: 10.1016/s0140-6736(16)30466-4.Peer-Reviewed Original ResearchConceptsHepatitis B virusHepatitis C virusViral hepatitisChronic hepatitis B virusBurden of HIVOpioid agonist therapyPrevalence of HIVTreatment of HIVIncarceration of peopleComprehensive literature searchAgonist therapyActive tuberculosisHIV transmissionC virusB virusGlobal burdenPrevention interventionsGeneral populationGlobal epidemiologyHIVDrug useTuberculosisLiterature searchLarge-scale outbreaksHepatitisCost-Effectiveness of Single- Versus Generic Multiple-Tablet Regimens for Treatment of HIV-1 Infection in the United States
Sweet DE, Altice FL, Cohen CJ, Vandewalle B. Cost-Effectiveness of Single- Versus Generic Multiple-Tablet Regimens for Treatment of HIV-1 Infection in the United States. PLOS ONE 2016, 11: e0147821. PMID: 26808503, PMCID: PMC4725959, DOI: 10.1371/journal.pone.0147821.Peer-Reviewed Original ResearchConceptsSingle-tablet regimensSubstantial price reductionsTenofovir disoproxil fumarate/emtricitabineCost-effectiveness thresholdIncremental cost-effectiveness ratioGeneric medicationsDaily single-tablet regimensDisoproxil fumarate/emtricitabineCost-effectiveness ratioElvitegravir/cobicistatCombination antiretroviral therapyHIV-1 patientsSingle-tablet regimenHigher inpatient costsHIV-1 infectionIncremental lifetime costPrice reductionEconomic outcomesMicrosimulation modelSuch policiesGeneric lamivudineTablet regimensAntiretroviral therapyU.S. settingsComplex regimens